Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Newer markers for hepatocellular carcinoma.

Jorge A Marrero1, Anna S F Lok

  • 1Division of Gastroenterology, University of Michigan, 3912 Taubman Center, Ann Arbor, Michigan 48109-0362, USA. jmarrero@umich.edu

Gastroenterology
|October 28, 2004

Related Experiment Videos

View abstract on PubMed

Summary
This summary is machine-generated.

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Newer Markers For Hepatocellular Carcinoma.

    • Early detection of liver cancer (hepatocellular carcinoma, HCC) is crucial. Current surveillance methods like alpha-fetoprotein (AFP) lack sensitivity, highlighting the need for better biomarkers.

    Area of Science:

    • Hepatology and Oncology
    • Biomarker Discovery
    • Cancer Surveillance

    Background:

    • Hepatocellular carcinoma (HCC) incidence is rising globally, with poor survival rates due to late diagnosis.
    • Cirrhosis is the primary risk factor for HCC development.
    • Current surveillance using alpha-fetoprotein (AFP) and ultrasonography has limitations in sensitivity and practicality.

    Purpose of the Study:

    • To highlight the urgent need for novel, sensitive, and specific biomarkers for early HCC detection.
    • To discuss the limitations of existing biomarkers and surveillance strategies.
    • To emphasize the importance of a structured validation framework for new biomarkers.

    Main Methods:

    • Review of current literature on HCC biomarkers and surveillance methods.
    • Analysis of limitations in existing studies, including sample size and assay heterogeneity.
    • Examination of the National Cancer Institute's proposed biomarker validation phases.

    Main Results:

    • Existing biomarkers like des-gamma carboxyprothrombin and IGF-1 show promise but lack clinical validation.
    • Current literature suffers from small sample sizes, inconsistent methodologies, and limited longitudinal data.
    • A significant gap exists in validated, non-invasive biomarkers for early HCC detection.

    Conclusions:

    • Novel biomarkers are urgently required for effective early detection of hepatocellular carcinoma.
    • A standardized, rigorous validation process is essential for clinical implementation of new HCC biomarkers.
    • The National Cancer Institute's framework offers a roadmap for future biomarker validation studies.

    Related Experiment Videos